Potential Biomarker May Indicate T-VEC Efficacy
March 18, 2025
A new study from Harvard University and the Massachusetts General Hospital may have uncovered a biomarker indicating a strong response…
The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.
If you have an idea for a future article, please reach out to us on our contact page!
Colitis – A Common but Serious Adverse Event
December 10, 2024
Immune-related adverse events (irAEs) are unintended consequences of immunotherapies used in cancer treatment. Side effects can range from mild to…
Limits of Success Shown for the Combination of Ipilimumab with Nivolumab
December 10, 2024
Immunotherapy is a resounding success for the treatment of many cancer types, including those malignancies which previously had no reliable…
Genetics Define Biomarkers of Response to Immunotherapy
December 10, 2024
Immune checkpoint inhibitor (ICI) therapy, such as nivolumab, pembrolizumab, atezolizumab or combinations with ipilimumab, can be extremely impactful for treating…